Frankenius Equity AB 13D and 13G filings for TriSalus Life Sciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-04 07:33 am Purchase | 2025-07-31 | 13D | TriSalus Life Sciences, Inc. TLSI | Frankenius Equity AB | 6,989,748 14.000% | 257,232 (+3.82%) | Filing |
| 2025-05-02 4:17 pm Purchase | 2025-04-30 | 13D | TriSalus Life Sciences, Inc. TLSI | Frankenius Equity AB | 6,732,516 20.500% | 243,797 (+3.76%) | Filing |
| 2024-12-19 4:12 pm Purchase | 2024-12-17 | 13D | TriSalus Life Sciences, Inc. TLSI | Frankenius Equity AB | 6,488,719 20.900% | 90,943 (+1.42%) | Filing |
| 2023-08-21 4:33 pm Purchase | 2023-08-10 | 13D | TriSalus Life Sciences, Inc. TLSI | Frankenius Equity AB | 6,397,776 24.100% | 6,397,776 (New Position) | Filing |